Merck is the latest company to weather bad news in the Alzheimer's drug race, halting a late -
stage trial yesterday in an experimental amyloid - targeting candidate called verubecestat after a data monitoring committee said there was «virtually no chance of finding a positive clinical effect,» Reuters reported.
Not exact matches
Activists often slam large pharmaceutical companies for failing to develop drugs that are of critical importance to the developing world.Andrew Witty, GlaxoSmithKline's youthful chief executive, gave those critics pause
yesterday in a speech to the Council on Foreign Relations in New York City.Witty promised to sell the company's malaria vaccine that is in late -
stage clinical
trials in Africa for no more than a 5 percent profit.
Nobody has received an early copy of the upcoming title yet, but the
stage play did have a
trial run
yesterday and here is what the critics are saying.